ANSI ASQ National Accreditation Board (ANAB) has awarded whole genome sequencing and bioinformatics company, Inocras Inc., accreditation to the ISO 15189 standard under its ISO 15189 Medical Laboratories Accreditation Program. Notably, Inocras is one of very few companies in the world with a CAP/CLIA/ISO 15189 accredited lab performing whole genome sequencing for cancer.

This accreditation is based on the International Organization for Standardization (ISO) 15189 Standard, which establishes benchmarks for laboratories' technical competence. The standard prioritizes patient safety and risk reduction while defining specific quality and competence requirements for medical laboratories.

The ANAB medical testing accreditation program aims to ensure the quality of medical testing laboratories and enhance patient care by supporting compliance with ISO 15189. This standard is intended to promote patient well-being and meet the needs of laboratory users by fostering trust in the competence and quality of medical laboratories.

Recognized internationally, ISO 15189 was developed with input from medical, scientific, and clinical experts. It outlines requirements for diagnostic laboratories to demonstrate their ability to provide timely, accurate, and dependable results. Additionally, the standard seeks to improve the efficiency of laboratory management systems, minimize the likelihood of invalid results, and reduce risks to patients, laboratory staff, the public, and the environment.

“Earning ISO 15189 accreditation was a cross-functional effort that took over a year in the making, building upon our CAP/CLIA foundation and emphasizing process improvement. With our company culture focused on quality, this accreditation allows us to showcase our quality focus and our determination to serve our patients with the best possible product," said Stephanie Ferguson, Chief Clinical Operations Officer at Inocras. “Quality is everyone's job, and we are committed to the delivery of exceptional laboratory quality for researchers, as well as exceptional quality care for patients."

About Inocras Inc:

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision and RareVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone. For more information, please visit inocras.com and follow Inocras LinkedIn page

View source version on businesswire.com: https://www.businesswire.com/news/home/20241210561551/en/